Key Points
- ISB 2001 achieved a 75% response rate in a Phase 1 trial for multiple myeloma.
- The treatment was safe, with no dose-limiting side effects and only one severe adverse event.
- Out of 12 patients who could be evaluated for treatment response, 9 showed positive results, including one patient who achieved a stringent complete response with no detectable disease.
- IGI is developing ISB 2001 as a first-in-class trispecific antibody using its BEAT® technology platform.
- The complete results will be presented at the American Society of Hematology Annual Meeting in December 2024.
- IGI is a partnership between Ichnos Sciences and Glenmark Pharmaceuticals, focused on creating new cancer therapies.
Looma News
Ichnos Glenmark Innovation (IGI) revealed the results of its Phase 1 clinical trial for ISB 2001, an experimental drug for treating relapsed or refractory multiple myeloma. The trial showed that 75% of patients responded to the treatment, with 9 out of 12 patients showing positive results. One of these patients achieved a stringent complete response, with no detectable disease. The treatment was well-tolerated, with no dose-limiting side effects and only one severe adverse event reported. None of the patients had to stop treatment during the trial.
ISB 2001 is being developed as a first-in-class trispecific antibody using IGI’s BEAT® technology. This drug targets BCMA and CD38 on multiple myeloma cells, as well as CD3 on T cells. Dr. Hang Quach from the University of Melbourne will present these results at the upcoming American Society of Hematology Annual Meeting in San Diego on December 9, 2024.
IGI is a collaboration between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Ltd., focused on developing new cancer treatments. The company brings together expertise in biologics and small molecules, with more than 150 scientists working across research centers in the USA, Switzerland, and India. IGI is advancing several promising therapies, and data on another drug, ISB 1442, will also be shared during the conference’s poster session.
